Organon & Co sells prescription pharmaceuticals focused on three areas: women's health (contraceptives like Nexplanon and fertility drugs like Follistim), established off-patent branded medicines, and biosimilars in immunology and oncology. Customers are primarily patients and healthcare providers globally. Revenue comes from product sales across these three segments, with women's health as the differentiated piece and established brands/biosimilars providing volume-driven income.
Employees10,000IPOMay 14, 2021SIC2834HQ30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
52.7%
Operating Margin
19.0%
EBITDA Margin
21.4%
Net Margin
3.4%
OCF Margin
12.0%
FCF Margin
7.1%
Returns on Capital
ROE
24.3%
ROA
1.6%
ROIC
5.0%
ROCE
9.0%
ROC (Greenblatt)
36.0%
3Y ROIIC
−39.3%
Consistency
Years Profitable / 10Y
8
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
17.87
Forward P/E
3.99
P/E ex-NRI
4.99
Shiller P/E (CAPE)
—
Cash Flow Multiples
P/FCF
8.32
P/OCF
4.90
P/Owner Earnings
19.62
FCF Yield
12.01%
Enterprise Value Multiples
EV / EBIT
11.48
EV / Forward EBIT
7.47
EV / EBITDA
8.38
EV / Forward EBITDA
6.76
EV / Revenue
1.80
EV / Forward Revenue
2.83
Asset / Sales
P/S
0.59
P/B
3.59
P/Tangible Book
—
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
0.58%
Forward Dividend Yield
0.58%
3Y Dividend Growth
−32.8%
Payout Ratio
0.03
5Y Yield on Cost
0.58%
Buybacks & Dilution
3Y Buyback Ratio
−0.80%
Combined
Shareholder Yield
6.72%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
8.50
Gross Debt / EBITDA
6.51
Cash / Debt
0.13
Equity / Assets
0.08
Coverage
Interest Coverage
2.49
Short-Term Liquidity
Current Ratio
1.95
Quick Ratio
1.44
Cash Ratio
0.43
Composite Scores
Piotroski F-Score
5
Altman Z-Score
1.25
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-08-14
$0.02
2026-09-10
2026-05-11
$0.02
2026-06-11
2026-02-23
$0.02
2026-03-12
2025-11-20
$0.02
2025-12-11
2025-08-15
$0.02
2025-09-11
2025-05-12
$0.02
2025-06-12
2025-02-24
$0.28
2025-03-13
2024-11-12
$0.28
2024-12-12
2024-08-16
$0.28
2024-09-12
2024-05-10
$0.28
2024-06-13
10 of 21
View allDate
Transcript
Type
2026-07-23
Organon & Co Extraordinary Shareholders Meeting Transcript
Shareholders and Annual Meetings
2026-06-09
Organon & Co Annual Shareholders Meeting Transcript
Shareholders and Annual Meetings
2026-02-12
Q4 2025 Organon & Co Earnings Call Transcript
Earnings Call
2025-12-03
Organon & Co at Piper Sandler Healthcare Conference Transcript
Conference Presentations
2025-11-10
Q3 2025 Organon & Co Earnings Call Transcript
Earnings Call
2025-08-05
Q2 2025 Organon & Co Earnings Call Transcript
Earnings Call
2025-05-01
Q1 2025 Organon & Co Earnings Call Transcript
Earnings Call
2025-02-13
Q4 2024 Organon & Co Earnings Call Transcript
Earnings Call
2024-10-31
Q3 2024 Organon & Co Earnings Call Transcript
Earnings Call
2024-08-06
Q2 2024 Organon & Co Earnings Call Transcript
Earnings Call
10 of 30
5-Step DuPont Analysis
ROE %
24.04%
×
×
Net Margin %
3.41%
×
×
Operating Margin %
19.00%
Operating Income
$1.16B
÷
Revenue
$6.13B
×
Tax Burden
0.4257
Net Income
$209M
÷
Pretax Income
$491M
×
Interest Burden
0.4218
Pretax Income
$491M
÷
Operating Income
$1.16B
×
Asset Turnover
0.46
÷
Revenue
$6.13B
÷
Average Total Assets
$13.34B
Begin Total Assets
$13.50B
End Total Assets
$13.18B
×
Equity Multiplier
15.34
÷
Avg Total Assets
$13.34B
÷
Avg Stockholders Equity
$870M
Begin Equity
$733M
End Equity
$1.01B
Top institutional holders
Q2 2026| Holder | Shares | Chg. shares | |
|---|---|---|---|
| BlackRock, Inc. | 32.1M | +339.8K | $434.05M |
| Pentwater Capital Management LP | 18.1M | new | $245.07M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 15.1M | -6.7M | $204.89M |
| VANGUARD CAPITAL MANAGEMENT LLC | 11.9M | +172.8K | $161.26M |
| STATE STREET CORP | 9.7M | -297.4K | $130.79M |
| GOLDMAN SACHS GROUP INC | 5.2M | +3.6M | $70.39M |
| UBS Group AG | 4.9M | +1.4M | $65.76M |
| GEODE CAPITAL MANAGEMENT, LLC | 4.8M | +56.3K | $65.22M |
| ALLIANCEBERNSTEIN L.P. | 4.8M | +4.0M | $28.48M |
| Man Group plc | 4.2M | new | $56.60M |
10 of 646
View allTop insider holdings
as reported| Insider | Shares held | |
|---|---|---|
| Ali KevinOfficer | 282.7K | $3.89M |
| WALSH MATTHEW MOfficer | 212.7K | $2.93M |
| Morrissey Joseph T. Jr.Officer | 123.1K | $1.69M |
| Stahler Rachel AOfficer | 116.1K | $1.60M |
| Falcione AaronOfficer | 101.4K | $1.40M |
| Weaver KirkeOfficer | 92.6K | $1.27M |
| COX CARRIE SMITHOfficer | 90.3K | $1.24M |
| Nisita VittorioOfficer | 70.6K | $971.7K |
| Karp DanielOfficer | 69.5K | $957.0K |
| DiMarco KathrynOfficer | 38.7K | $533.1K |
10 of 13
View allRecent insider activity
through Aug 11, 2026| Insider | Action | Shares | Date | |
|---|---|---|---|---|
| Arjona Ferreira Juan CamiloOfficer | Option Exercise (Rule 16b-3 Exempt) | +11.5K | $0 | Aug 11, 2026 |
| Arjona Ferreira Juan CamiloOfficer | Tax Withholding | -4.1K | $56.3K | Aug 11, 2026 |
| Drinane Juliana PapaOfficer | Open-Market or Private Sale | -14.8K | $200.3K | Aug 5, 2026 |
| Holzbaur LynetteOfficer | Other Acquisition or Disposition | +46 | $0 | May 6, 2026 |
| Holzbaur LynetteOfficer | Open-Market or Private Sale | -26.4K | $353.1K | May 6, 2026 |
| Drinane Juliana PapaOfficer | Option Exercise (Rule 16b-3 Exempt) | +6.4K | $0 | Mar 31, 2026 |
| Drinane Juliana PapaOfficer | Tax Withholding | -2.2K | $12.5K | Mar 31, 2026 |
| Drinane Juliana PapaOfficer | Option Exercise (Rule 16b-3 Exempt) | +10.1K | $0 | Mar 31, 2026 |
| Drinane Juliana PapaOfficer | Tax Withholding | -3.5K | $19.7K | Mar 31, 2026 |
| Arjona Ferreira Juan CamiloOfficer | Option Exercise (Rule 16b-3 Exempt) | +13.4K | $0 | Mar 31, 2026 |
10 of 444
View all